

NHSBT Finance Report

June 2022

| Contents | Page |
|---------------------------------|------|
| Executive Summary | 2 |
| Financial Performance Headlines | 3-4 |
| NHSBT – Summary I&E Statement | 5 |
| Divisional I&E statements | 6-9 |
| Cash & Debtors | 10 |
| Contribution Statement | 11 |

Executive Summary

June Results: NHSBT overall financial position ahead of plan year to date.

- £4.5m ahead of budget year to date, reflecting underspends in pay and non pay across all divisions.
- NHSBT cash at the end of June was £70m. The forecast Blood and Group cash reserves for the year end is £17m.
- 2022/23 full year forecast is being prepared.
- Pay costs in 2022/23 remain the primary uncertainty (3% increase assumed – currently phased into Q4 budget)

Blood and Group: £2.8m ahead of plan, mostly due to phasing of expenditure

- Focus on blood collection / red cell stocks and Testing Development Programme.
- Highly uncertain environment, likely to impact the timing/delivery of planned productivity benefits
- To be reviewed as part of the forecast and 2023/24 indicative budget review currently underway

Clinical Services: £1.3m ahead of plan

- All business units broadly on plan to deliver plan contributions
- CBC at risk of not achieving full year income target.

Plasma: In line with plan

- Discussions ongoing with NHS England to finalise an SLA which will fully fund collection costs from mid 2023/24 onwards.
- ABC allocation £0.8m lower than budget estimates (carry forward as cash to 2022/23)


ODT: £0.3m behind plan due to timing of transformation spend

- 2022/23 likely to be cash positive versus plan
- The key issue remains the need for early confirmation of funding for 2023/24 and its impact on capacity/activity levels.
- Note – TES is £07m ahead of plan year to date.

2022/23 NHSBT Financial Performance Headlines - June 2022


Year to date surplus of £6.7m for NHSBT overall, £4.5m ahead of plan

Blood and Group Net Income & Expenditure (excl. Change Programme and Plasma)




Blood and Group ahead of plan, driven by underspends in Group Services - detail on page 5 & 6

Clinical Services Net Income & Expenditure (Business unit contribution)




£1.3m favourable variance – combination of higher activity and vacancies across Business Units – detail on page 7

Organ Donation & Transplantation Net Funding & Expenditure




ODT marginally behind plan - detail on page 8
In addition, TES is reporting £0.7m ahead of plan

Blood and Group Change Programme Full Year Outturn



The transformation forecast will be reported on completion of the NHSBT Q1 forecast process

NHSBT Cash Flow 2022/23



Forecast cash balance at the end of March 2023 is £42m, this will be updated to reflect the Q1 forecast.

NHSBT I&E Full Year Outturn







NHSBT Full Year Budget -£8.1m deficit




Note: This profile assumes that the 3% pay award is phased into month 12. When the actual settlement is confirmed, budget pay costs will be rephased to match the impact of the award.

2022/23 NHSBT Financial Performance Headlines – June 2022

Surpluses across all divisions

| | | | | | |
|------------------------------------|---|-------------------|----------------|---|---|
| Year to date position (M02) | £6.7m surplus VS £2.1m budget surplus | Blood/Group | +£2.8m | Stock movement in Blood Supply offset by positive (timing) variances in DDTS and Estates |  |
| | | Plasma | +£0.0m | In line with plan |  |
| | | Clinical Services | +£1.3m | Increased TAS and CMT activity combined with unfilled vacancies across the division. |  |
| | | OTDT | + £0.4m | ODT (-£0.3m) – higher than plan transformation, to be met by cash reserves TES (+£0.7m) – higher cornea and serum eye drops activity |  |

| | | | | | |
|--------------------------|---------------------------------------|-------------------|---------------|------------------------------------|----------------------|
| Full Year Outturn | Full Year Budget Deficit £8.1m | Blood/Group | +£0.0m | The Q1 forecast is being prepared. | <input type="text"/> |
| | | Plasma | +£0.0m | | <input type="text"/> |
| | | Clinical Services | +£0.0m | | <input type="text"/> |
| | | OTDT | +£0.0m | | <input type="text"/> |

| | | | | |
|-------------------------|--------------------------|------------------|---|---|
| Cash and Debtors | Cash balance £70m | Debtor Days | 13 days – ahead of target (22 days) |  |
| | | 90+ day overdues | £0.7m (within £0.5m - £1.0m target range). |  |
| | | Cash | Cash balance at then end of June 2022 was £70m. |  |

NHSBT Summary I&E statement - June 2022

| Jun | | | Blood and Group | WTE | | Year to Date | | | Budget | Prev. Yr Actual |
|-----------------|-----------------|--------------|---|--------------|-----------------|-----------------|-----------------|-----------------|------------------|-----------------|
| Budget | Actual | Variance | | Budget | Actual | Budget | Actual | Variance | | |
| 1,036 | 1,036 | 0 | Programme Funding - Corporate | | 3,107 | 3,107 | 0 | 12,428 | 11,461 | |
| 25,462 | 25,626 | 164 | Blood & Components Income | | 76,515 | 76,701 | 186 | 306,827 | 292,274 | |
| 280 | 282 | 2 | Blood Supply Other Income | | 839 | 949 | 110 | 3,512 | 3,864 | |
| 500 | 613 | 113 | Group Services Income | | 1,551 | 1,726 | 175 | 6,091 | 5,272 | |
| 27,278 | 27,556 | 279 | Blood and Group Income | | 82,012 | 82,482 | 471 | 328,857 | 312,872 | |
| 279 | (623) | (902) | Blood Supply Cost of Sales | 0 | 561 | (895) | (1,456) | 0 | (2,305) | |
| (13,518) | (13,770) | (252) | Blood Supply Operations | 2,462 | 2,471 | (41,030) | (41,436) | (406) | (163,952) | |
| (15,140) | (14,204) | 936 | Group Services | 1,220 | 1,118 | (45,037) | (42,341) | 2,696 | (182,936) | |
| (1,196) | (282) | 914 | Change Programme | 0 | 24 | (2,662) | (1,144) | 1,518 | (16,999) | |
| (29,575) | (28,878) | 696 | Blood and Group Expenditure | 3,682 | 3,613 | (88,168) | (85,816) | 2,352 | (363,886) | |
| (2,297) | (1,322) | 975 | Blood and Group Total | 3,682 | 3,613 | (6,157) | (3,334) | 2,823 | (35,029) | |
| | | | Plasma for Medicine | | | | | | | |
| 1,176 | 1,383 | 207 | Programme Funding - Plasma | | 3,527 | 4,412 | 885 | 14,107 | 29,484 | |
| 682 | 778 | 96 | Plasma for Diagnostics Income | | 1,364 | 778 | (585) | 7,500 | 0 | |
| 1,857 | 2,161 | 304 | Plasma Funding | | 4,890 | 5,190 | 300 | 21,607 | 29,484 | |
| 0 | 0 | 0 | Plasma for Medicine Cost of Sales | 0 | 0 | 0 | 0 | 0 | 1,076 | |
| (857) | (1,161) | (304) | Plasma for Medicine | 122 | 129 | (2,593) | (2,892) | (300) | (16,493) | |
| (857) | (1,161) | (304) | Plasma Expenditure | | (2,593) | (2,892) | (300) | (16,493) | (28,408) | |
| 1,000 | 1,000 | 0 | Plasma for Medicine Total | 122 | 129 | 2,298 | 2,298 | 0 | 5,113 | |
| | | | Clinical Services | | | | | | | |
| 374 | 373 | (1) | Programme Funding - Diagnostics, Therapeutic Apheresis & Stem Cells | | 1,122 | 1,120 | (3) | 4,489 | 4,162 | |
| 6,154 | 6,289 | 135 | Diagnostic and Therapeutic Services Income | | 17,037 | 17,794 | 757 | 72,420 | 69,057 | |
| 6,528 | 6,662 | 134 | Clinical Services Income | | 18,159 | 18,913 | 755 | 76,909 | 73,219 | |
| (5,379) | (5,057) | 323 | Clinical Services Operations | 803 | 730 | (16,056) | (15,274) | 782 | (65,839) | |
| 0 | (65) | (65) | Clinical Services Change Programme | 0 | 1 | 0 | (249) | (249) | (3,751) | |
| (5,379) | (5,121) | 258 | Clinical Services Expenditure | | (16,056) | (15,524) | 533 | (69,590) | (61,119) | |
| 1,149 | 1,541 | 392 | Clinical Services Total | 803 | 731 | 2,103 | 3,390 | 1,287 | 7,319 | |
| | | | Organ Donation & Transplantation | | | | | | | |
| 6,665 | 6,620 | (45) | Programme Funding (DHSC and Other UK Health Authorities) | | 19,996 | 19,988 | (7) | 79,983 | 81,504 | |
| 170 | 170 | 0 | Programme Funding - Opt Out | | 510 | 510 | 0 | 2,041 | 0 | |
| 284 | 338 | 54 | NHSE Funding | | 851 | 922 | 71 | 3,404 | 1,921 | |
| 7,119 | 7,128 | 9 | ODT Income | | 21,357 | 21,421 | 64 | 85,428 | 83,425 | |
| (5,587) | (5,798) | (211) | Organ Donation and Transplantation Operations | 490 | 473 | (16,975) | (16,645) | 330 | (71,926) | |
| (358) | (681) | (323) | Organ Donation and Transplantation Change Programme | 30 | 24 | (1,075) | (1,788) | (713) | (4,488) | |
| (5,945) | (6,479) | (534) | ODT Expenditure | | (18,049) | (18,433) | (384) | (76,414) | (73,876) | |
| 1,174 | 649 | (525) | ODT Total | 520 | 497 | 3,308 | 2,988 | (320) | 9,015 | |
| | | | Tissues and Eye Services | | | | | | | |
| 1,221 | 1,323 | 101 | Tissue & Eye Services Income | | 3,627 | 4,121 | 494 | 17,937 | 15,062 | |
| 46 | 46 | 0 | Programme Funding - Tissue and Eye Services | | 139 | 139 | 0 | 554 | 0 | |
| 1,268 | 1,369 | 101 | TES Income | | 3,765 | 4,259 | 494 | 18,491 | 15,062 | |
| (1,057) | (960) | 97 | Tissue and Eye Services Operations | 153 | 133 | (3,199) | (2,948) | 250 | (13,043) | |
| (1,057) | (960) | 97 | TES Expenditure | | (3,199) | (2,948) | 250 | (13,043) | (12,468) | |
| 210 | 409 | 199 | TES Total | 153 | 133 | 566 | 1,311 | 745 | 5,449 | |
| | | | NHSBT Summary | | | | | | | |
| 44,049 | 44,876 | 827 | Income | | 130,183 | 132,266 | 2,083 | 531,293 | 514,063 | |
| (42,813) | (42,599) | 214 | Expenditure | 5,280 | 5,102 | (128,065) | (125,613) | 2,452 | (539,426) | |
| 1,236 | 2,277 | 1,041 | NHSBT Surplus/(Deficit) | 5,280 | 5,102 | 2,118 | 6,653 | 4,535 | (8,133) | |


Blood and Group - June 2022

| Blood Supply |
|--|
| (£)m |
| Blood and Component Income |
| Other Blood Supply Income |
| Total Income |
| Cost of Sales - Blood Component Stock Movement |
| Blood Donation |
| Manufacturing, Testing & Issue |
| Logistics |
| Total Expenditure |

| WTE | |
|--------------|--------------|
| Bud. | Act. |
| | |
| | |
| | |
| 1,420 | 1,473 |
| 732 | 692 |
| 310 | 305 |
| 2,462 | 2,471 |

| Year to Date Actual | | |
|---------------------|---------------|--------------|
| Bud. | Act. | Var. |
| 76.5 | 76.7 | 0.2 |
| 0.8 | 0.9 | 0.1 |
| 77.4 | 77.6 | 0.3 |
| 0.6 | (0.9) | (1.5) |
| (19.2) | (19.2) | 0.0 |
| (16.4) | (16.6) | (0.2) |
| (5.4) | (5.7) | (0.3) |
| (40.5) | (42.3) | (1.9) |

| FY Budget |
|----------------|
| 306.8 |
| 3.5 |
| 310.3 |
| 0.0 |
| (75.3) |
| (66.4) |
| (22.2) |
| (164.0) |



| |
|---|
| Blood Supply Operating Surplus/(Deficit) |
|---|

| | |
|--------------|--------------|
| 2,462 | 2,471 |
|--------------|--------------|

| | | |
|-------------|-------------|--------------|
| 36.9 | 35.3 | (1.6) |
|-------------|-------------|--------------|

| |
|--------------|
| 146.4 |
|--------------|

| |
|--|
| Group Services (incl. Change Programme) |
|--|

| | |
|--------------|--------------|
| 1,220 | 1,142 |
|--------------|--------------|

| | | |
|---------------|---------------|------------|
| (43.0) | (38.7) | 4.4 |
|---------------|---------------|------------|

| |
|----------------|
| (181.4) |
|----------------|

Group Services detail on page 6

| |
|--|
| Blood and Group Surplus/(Deficit) |
|--|

| | |
|--------------|--------------|
| 3,682 | 3,613 |
|--------------|--------------|

| | | |
|--------------|--------------|------------|
| (6.2) | (3.3) | 2.8 |
|--------------|--------------|------------|

| |
|---------------|
| (35.0) |
|---------------|

At Q1, Blood Supply are £1.6m behind plan. The primary driver behind this adverse variance is the Blood and Component finished stock movement. This is a reflection of the current stock challenge Blood Supply are facing, given that red cell stocks are significantly below target levels.

Blood Supply operations are also starting to see the impact of higher inflation as adverse costs trends (over and above what was already budgeted) are being reporting against courier and fuel expenditure in Logistics. This is broadly offset, however, by increased click and collect income, and higher increased income from private hospitals.

Group Services - June 2022

| Group Services (£)m | WTE | | Year to Date Actual | | | FY Budget |
|---|--------------|--------------|---------------------|---------------|------------|----------------|
| | Bud. | Act. | Bud. | Act. | Var. | |
| Programme Funding | | | 3.1 | 3.1 | 0.0 | 12.4 |
| Group Services Income | | | 0.4 | 0.5 | 0.1 | 1.7 |
| Medical | | | 0.4 | 0.4 | (0.0) | 1.6 |
| Research & Development | | | 0.7 | 0.9 | 0.2 | 2.8 |
| Total Income | | | 4.7 | 4.8 | 0.2 | 18.5 |
| Chief Executive and Board | 4 | 5 | (0.2) | (0.2) | (0.0) | (0.8) |
| Donor Experience | 191 | 171 | (6.1) | (5.5) | 0.5 | (23.9) |
| Quality | 128 | 124 | (2.1) | (1.9) | 0.2 | (8.6) |
| Estates & Facilities | 80 | 77 | (12.3) | (11.5) | 0.8 | (49.0) |
| Finance | 111 | 98 | (1.8) | (1.8) | (0.0) | (7.3) |
| Strategy and Transformation | 14 | 11 | (0.3) | (0.3) | (0.0) | (1.0) |
| People | 153 | 145 | (2.7) | (2.6) | 0.1 | (11.0) |
| Digital, Data and Technology Services | 301 | 267 | (10.7) | (9.6) | 1.0 | (44.3) |
| Research & Development | 47 | 39 | (1.6) | (1.7) | (0.1) | (6.3) |
| Medical | 193 | 181 | (4.3) | (4.0) | 0.2 | (18.0) |
| Miscellaneous and Capital Charges | 0 | 0 | (3.1) | (3.2) | (0.1) | (12.5) |
| Total Expenditure | 1,220 | 1,118 | (45.0) | (42.3) | 2.7 | (182.9) |
| Operating Surplus/(Deficit) | 1,220 | 1,118 | (40.4) | (37.5) | 2.9 | (164.4) |
| Change Programme | 0 | 24 | (2.7) | (1.1) | 1.5 | (17.0) |
| Group Services Surplus/(Deficit) | 1,220 | 1,142 | (43.0) | (38.7) | 4.4 | (181.4) |

At Q1, Group Services are reporting a favourable variance of £4.4m against plan. This is driven by small surpluses across most Directorates. The underspends reported against Estates & Facilities and Donor Experience are mostly a result of phasing and budget profiling differences. Higher spend is anticipated later in the year and will bring the position back in line with plan.

Clinical Services - June 2022 (operating contributions - pre ABC analysis)

| (€)m | WTE | | Year to Date Actual | | | Full Year Budget |
|--|------------|------------|---------------------|--------------|--------------|------------------|
| | Budget | Actual | Budget | Actual | Variance | |
| Red Cell Immunohematology (inc Reagents and IBGRL) | | | | | | |
| Income | | | 5.5 | 5.6 | 0.1 | 22.6 |
| Expenditure | | | (4.2) | (4.0) | 0.2 | (17.2) |
| RCI - direct contribution | 250 | 229 | 1.3 | 1.6 | 0.3 | 5.3 |
| Histocompatibility & Immunogenetics | | | | | | |
| Income | | | 3.8 | 4.0 | 0.1 | 16.0 |
| Expenditure | | | (3.8) | (3.8) | 0.0 | (15.7) |
| H&I - direct contribution | 177 | 172 | (0.0) | 0.1 | 0.1 | 0.3 |
| Pathology Total - WTE / direct contribution | | | | | | |
| | 427 | 401 | 1.3 | 1.8 | 0.5 | 5.6 |
| Therapeutic Apheresis Services | | | | | | |
| Income | | | 2.8 | 3.7 | 0.8 | 11.8 |
| Expenditure | | | (2.3) | (2.5) | (0.2) | (9.4) |
| TAS - direct contribution | 99 | 92 | 0.6 | 1.2 | 0.6 | 2.5 |
| Cord Blood Bank and British Bone Marrow Registry | | | | | | |
| Income - prices | | | 1.9 | 1.8 | (0.1) | 7.6 |
| Expenditure | | | (0.8) | (0.8) | 0.1 | (3.4) |
| SCGT - direct contribution | 46 | 43 | 1.1 | 1.1 | (0.0) | 4.2 |
| CBC | | | | | | |
| Income | | | 0.9 | 0.4 | (0.5) | 4.4 |
| Expenditure | | | (0.9) | (1.0) | (0.1) | (3.6) |
| CBC - direct contribution | 37 | 31 | 0.0 | (0.6) | (0.6) | 0.8 |
| Cellular & Molecular Therapies (exc CBC) | | | | | | |
| Income | | | 3.2 | 3.5 | 0.3 | 14.4 |
| Expenditure | | | (2.5) | (2.2) | 0.4 | (10.4) |
| CMT I&E | 108 | 95 | 0.7 | 1.3 | 0.6 | 4.0 |
| CAGT Total - WTE / direct contribution | | | | | | |
| | 290 | 262 | 2.3 | 2.9 | 0.6 | 11.4 |
| Transfusion excl. R&D / Medical (within Group Services) | | | | | | |
| | 38 | 35 | (0.3) | (0.2) | 0.1 | (1.1) |
| DTS Management | | | | | | |
| | 47 | 32 | (1.2) | (0.9) | 0.3 | (4.9) |
| TOTAL - WTE / Operating Surplus/(Deficit) | | | | | | |
| | 803 | 730 | 2.1 | 3.6 | 1.5 | 11.1 |
| Change Programme | | | | | | |
| | 0 | 1 | 0.0 | (0.2) | (0.2) | (3.8) |
| TOTAL - WTE / Clinical Services Surplus/(Deficit) | | | | | | |
| | 803 | 731 | 2.1 | 3.4 | 1.3 | 7.3 |

At Q1, Clinical Services (pre ABC analysis) is reporting £1.3m ahead of plan. This is predominately driven by higher income across TAS and CMT combined with vacancies reported within the Division;

Summary by Business Unit;

RCI; driven primarily by increased reference and on-call activity plus unfilled vacancies in the first quarter.


H&I; income marginally above plan driven by strong PGI performance.

TAS; favourable income position driven by a combination of the NHSE ECP sustainability allowance (Q1 only), increased Welsh ECP referrals and PEX activity. This is partially offset by increased harness spend due to this increased activity.

CBC; overall project now running at amber/red status due to expected delays in project income.

CMT; driven by favourable service income combined with pay benefits driven by a number of vacant posts.

Income growth in Clinical Services



Note: Excludes Medical and R&D funding.

ODT – June 2022

| ODT I&E (£)m | WTE | | Year to Date Actual | | | FY Budget |
|--|------------|------------|---------------------|---------------|--------------|---------------|
| | Bud. | Act. | Bud. | Act. | Var. | |
| Programme Funding | | | 17.3 | 17.3 | (0.1) | 69.4 |
| Other UK Health Authorities Funding | | | 3.2 | 3.2 | 0.1 | 12.6 |
| NHSE Funding | | | 0.9 | 0.9 | 0.1 | 3.4 |
| Total Funding | | | 21.4 | 21.4 | 0.1 | 85.4 |
| Operating Expenditure | 490 | 473 | (17.0) | (16.6) | 0.3 | (71.9) |
| Transformation | 30 | 24 | (1.1) | (1.8) | (0.7) | (4.5) |
| Total Expenditure | 520 | 497 | (18.0) | (18.4) | (0.4) | (76.4) |
| ODT Surplus/(Deficit) | 520 | 497 | 3.3 | 3.0 | (0.3) | 9.0 |
| Direct contribution to Group Services | | | | | | (10.8) |
| ODT Deficit (funded by cash) | | | | | | (1.8) |

The ODT funding envelope for 2022/23 is based on flat funding from DHSC/ The resulting deficit at operational level (£1.8m) will be met from cash reserves.

As at the end of Q1, ODT are reporting lower activity expenditure, which is more that offset by higher transformation expenditure than plan (timing).

Going into 2023/24 the underlying deficit is set to increase further, reflecting an incremental increase to activity (per the ODT strategy) and inflation pressures vs flat funding over the SR21 period. This funding gap will need to be addressed well in advance of 2023/24.

Tissue and Eye Services – June 2022

TES are reporting a strong performance against plan for most products. This is further improved by a positive stock movement and unfilled vacancies.

| TES I&E (£)m | WTE | | Year to Date Actual | | | FY Budget |
|--------------------------|------------|------------|---------------------|------------|------------|------------|
| | Bud. | Per Act. | Bud. | Act. | Var. | |
| Income | | | 3.8 | 4.3 | 0.5 | 18.5 |
| Cost of Sales | | | (0.1) | (0.0) | 0.1 | (0.5) |
| Expenditure | 153 | 133 | (3.1) | (2.9) | 0.2 | (12.5) |
| Surplus/(Deficit) | 153 | 133 | 0.6 | 1.3 | 0.7 | 5.4 |

Plasma for Medicine - June 2022

| Plasma for Medicine (£)m | WTE | | Year to Date | | | FY Budget |
|------------------------------------|------------|------------|--------------|------------|------------|------------|
| | Bud. | Act. | Bud. | Act. | Var. | |
| Programme Funding | | | 3.5 | 4.4 | 0.9 | 14.1 |
| Plasma for Diagnostics Income | | | 1.4 | 0.8 | (0.6) | 7.5 |
| Expenditure | 122 | 129 | (2.6) | (2.9) | (0.3) | (16.5) |
| Programme Surplus/(Deficit) | 122 | 129 | 2.3 | 2.3 | 0.0 | 5.1 |

For 2022/23, the Plasma plan is fully funded by a combination of cash reserves and Plasma for Diagnostics income.

Cash Flow – as at June 2022

| | Actual Apr-22 £k | Actual May-22 £k | Actual Jun-22 £k | Forecast Jul-22 £k | Forecast Aug-22 £k | Forecast Sep-22 £k | Forecast Oct-22 £k | Forecast Nov-22 £k | Forecast Dec-22 £k | Forecast Jan-23 £k | Forecast Feb-23 £k | Forecast Mar-23 £k | Total £k |
|--------------------------------------|------------------------|------------------------|------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|----------------|
| Opening bank balance | 64,676 | 72,432 | 75,293 | 69,908 | 94,207 | 95,953 | 91,351 | 80,824 | 78,112 | 75,071 | 75,254 | 63,753 | 64,676 |
| Receipts | | | | | | | | | | | | | |
| Debtors & Other Receipts | 33,604 | 39,970 | 34,671 | 37,708 | 38,932 | 37,656 | 38,841 | 37,687 | 38,918 | 37,804 | 38,073 | 37,388 | 451,252 |
| Revenue Cash Limit | 0 | 0 | 0 | 23,975 | 5,993 | 5,993 | 5,993 | 5,993 | 5,993 | 5,993 | 5,993 | 6,000 | 71,926 |
| Revenue Cash Limit - Pensions Uplift | 0 | 0 | 0 | 3,733 | 933 | 933 | 933 | 933 | 933 | 933 | 933 | 936 | 11,200 |
| Capital Cash Limit | 0 | 0 | 0 | 3,000 | 0 | 0 | 4,000 | | 4,000 | | 5,000 | 5,000 | 21,000 |
| Total Receipts | 33,604 | 37,621 | 32,169 | 67,069 | 43,287 | 43,474 | 48,287 | 43,287 | 48,287 | 43,304 | 48,287 | 47,771 | 555,378 |
| Payments | | | | | | | | | | | | | |
| Staff Expenses | 6,743 | 21,016 | 21,338 | 20,608 | 23,301 | 27,063 | 27,407 | 24,082 | 23,956 | 23,129 | 22,629 | 30,674 | 271,945 |
| Other Revenue Payments | 18,359 | 15,949 | 18,378 | 22,709 | 20,011 | 21,121 | 21,250 | 21,743 | 26,929 | 19,418 | 25,434 | 32,605 | 263,907 |
| Capital Charges Less DH Credit Due | 0 | 0 | 0 | 0 | 0 | 0 | 10,437 | 0 | 0 | 0 | 10,437 | 0 | 20,874 |
| Capital Payments | 746 | 144 | 340 | 800 | 800 | 1,000 | 1,200 | 1,500 | 2,000 | 2,000 | 3,000 | 7,470 | 21,000 |
| Total Payments | 25,848 | 34,760 | 37,553 | 42,770 | 41,541 | 48,076 | 58,814 | 45,999 | 51,328 | 43,121 | 59,788 | 69,196 | 577,726 |
| Closing bank balance | 72,432 | 75,293 | 69,909 | 94,207 | 95,953 | 91,351 | 80,824 | 78,112 | 75,071 | 75,254 | 63,753 | 42,328 | 42,328 |

| | | | |
|---|-------|-------|-------|
| Debtor Days (Target is 22 days) | 17 | 14 | 13 |
| YTD BPPC By Value % (Target is 95%) | 86.9% | 91.1% | 93.5% |
| YTD BPPC By Number % (Target is 95%) | 92.8% | 93.1% | 93.2% |

| Overdue Debtors NBS/ODT £000's | 1-30 Days overdue £000's | 31-60 Days overdue £000's | 61-90 Days overdue £000's | >90 Days overdue £000's | Total Overdue £000's |
|--------------------------------|--------------------------------|---------------------------------|---------------------------------|-------------------------------|----------------------------|
| Total Overdue Debtors | 4,353 | 1,871 | 490 | 686 | 7,400 |

| | May-22 | | Jun-22 | |
|--|-------------------------------|----------------------------|-------------------------------|----------------------------|
| | >90 Days overdue £000's | Total Overdue £000's | >90 Days overdue £000's | Total Overdue £000's |
| Top 5 > 90 days Overdue Debtors £000's | | | | |
| HCA INTERNATIONAL LTD | | | 153 | 250 |
| LANCASHIRE TEACHING HOSPITALS NHS FOUNDATION TRUST | | | 125 | 135 |
| GATESHEAD HEALTH NHS FOUNDATION TRUST | 45 | 233 | 94 | 297 |
| IMPERIAL COLLEGE HEALTHCARE NHS TRUST | 45 | 1,203 | | |
| ROYAL BERKSHIRE NHS FOUNDATION TRUST | 30 | 346 | | |
| HULL UNIVERSITY TEACHING HOSPITALS NHS TRUST | 30 | 182 | 53 | 167 |
| IMPERIAL COLLEGE HEALTHCARE NHS TRUST | | | 45 | 65 |
| CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LTD | 29 | 29 | | |
| Total 5 Overdue Debtors | 179 | 1,995 | 470 | 914 |
| Other Debtors | 235 | 6,776 | 216 | 6,486 |
| Total Overdue Debtors | 413 | 8,771 | 686 | 7,400 |

| Notional Split | £m |
|--------------------|-------------|
| Blood | 18.5 |
| Clinical Services | 5.8 |
| ODT | 9.2 |
| Plasma | 8.9 |
| NHSBT Total | 42.3 |

| >90 DAYS OVERDUE | Profile by Month | | | | | | | | | | | | | | | |
|------------------------------------|--------------------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|--|--|--|--|
| | Actual Apr-22 £000s | Actual May-22 £000s | Actual Jun-22 £000s | Actual Jul-22 £000s | Actual Aug-22 £000s | Actual Sep-22 £000s | Actual Oct-22 £000s | Actual Nov-22 £000s | Actual Dec-22 £000s | Actual Jan-23 £000s | Actual Feb-23 £000s | Actual Mar-23 £000s | | | | |
| | Target Range Between £0.5m and £1.0m | | | | | | | | | | | | | | | |
| Ledger Balance at month end | 330 | 413 | 686 | | | | | | | | | | | | | |

Contribution Statement– as at June 2022

Post allocation of costs via the ABC model

| Year to date Actual £m | Blood & Components inc. R&D | Plasma | Pathology | | CAGT | | | | TES | ODT | NHSBT |
|---|--------------------------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|---------------|----------------|
| | | | RCI | H&I | CMT | CBC | SCDT | TAS | | | |
| Income/Funding | | | | | | | | | | | |
| Prices | 77.6 | 0.0 | 5.3 | 3.4 | 3.3 | 0.0 | 1.2 | 3.5 | 4.1 | 0.0 | 98.4 |
| Central Funding from DHAs | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 3.2 | 3.2 |
| Grant in Aid (DHSC Funding) | 2.0 | 4.5 | 0.1 | 0.5 | 0.1 | 0.0 | 0.7 | 0.1 | 0.2 | 17.8 | 26.0 |
| Other | 1.8 | 0.8 | 0.3 | 0.1 | 0.2 | 0.4 | 0.0 | 0.1 | 0.0 | 1.0 | 4.7 |
| Total Income/Funding | 81.4 | 5.3 | 5.7 | 4.0 | 3.5 | 0.4 | 1.9 | 3.7 | 4.4 | 21.9 | 132.3 |
| Expenditure | | | | | | | | | | | |
| Variable Costs | (9.3) | (0.2) | (0.4) | (0.9) | (0.4) | (0.3) | (0.2) | (1.0) | (0.7) | (1.7) | (15.2) |
| Variable Contribution | 72.1 | 5.1 | 5.3 | 3.2 | 3.1 | 0.1 | 1.7 | 2.7 | 3.7 | 20.2 | 117.0 |
| Direct Costs | (32.8) | (2.7) | (3.2) | (1.9) | (1.7) | (0.6) | (0.9) | (1.4) | (2.4) | (16.4) | (64.2) |
| Direct Contribution | 39.2 | 2.4 | 2.1 | 1.2 | 1.4 | (0.5) | 0.7 | 1.3 | 1.3 | 3.8 | 52.9 |
| Direct Support Costs | (26.2) | (0.6) | (1.4) | (0.7) | (1.1) | (0.2) | (0.5) | (0.4) | (0.7) | (2.5) | (34.4) |
| Total Allocated Costs | (68.4) | (3.5) | (5.1) | (3.5) | (3.2) | (1.2) | (1.6) | (2.8) | (3.8) | (20.6) | (113.8) |
| Total Unallocated Costs | (5.8) | (0.3) | (0.4) | (0.3) | (0.3) | (0.1) | (0.1) | (0.2) | (0.3) | (1.8) | (9.6) |
| Operating Net Surplus / (Deficit) | 7.2 | 1.5 | 0.2 | 0.2 | 0.0 | (0.8) | 0.1 | 0.7 | 0.2 | (0.5) | 8.8 |
| Transformation | (1.0) | - | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | - | (1.0) | (2.1) |
| Net Surplus / (Deficit) Inc Transformation | 6.2 | 1.5 | 0.2 | 0.2 | 0.0 | (0.8) | 0.1 | 0.7 | 0.2 | (1.5) | 6.7 |
| Budget | 4.6 | 1.3 | (0.3) | (0.0) | (0.9) | (0.4) | 0.1 | 0.1 | (0.8) | (1.7) | 2.1 |
| Variance | 1.6 | 0.2 | 0.5 | 0.2 | 0.9 | (0.5) | 0.0 | 0.6 | 1.0 | 0.2 | 4.6 |
| RAG | G | G | G | G | G | R | G | G | G | G | G |

Blood at "Green" but results from the favourable group services and change programme position

Clinical Services are at "green", primarily as a result of income being ahead of plan and unfilled vacancies, however, CBC is reporting Red as income falls behind the budget.